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The gut flora are widely involved in the cometabolism with the host and have evident
effects on the metabolic phenotype of host. This study performed a metabolome
analysis of the intestinal microbiota specific for liver cirrhosis. The study population
included patients with Child-Turcotte-Pugh score of A (AP, n = 5) and B (BP,
n = 5), and control subjects (NM, n = 3). Metagenomic DNA from fecal microbiota
was extracted followed by metagenomic sequencing through Illumina MiSeq high
throughput sequencing of 16S rRNA regions. The detection of metabolites from fecal
samples was performed using high-performance liquid phase chromatography and
gas chromatography coupled with tandem mass spectrometry. Intestinal microbiota
community and metabolite analysis both showed separation of cirrhotic patients
from control participants, moreover, the microbiota–metabolite correlations changed in
cirrhotic patients. Fecal microbiota from cirrhotic patients, with the reduced diversity,
contained a decreased abundance of Bacteroidetes and an increased abundance
of Firmicutes and Proteobacteria compared with the normal samples. Analysis of
metabolome revealed a remarkable change in the metabolic potential of the microbiota
in cirrhotic patients, with specific higher concentrations of amine, unsaturated fatty acid,
and short-chain fatty acids, and lower concentrations of sugar alcohol and amino acid,
suggesting the initial equilibrium of gut microbiota community and co-metabolism with
the host were perturbed by cirrhosis. Our study illustrated the relationship between fecal
microbiota composition and metabolome in cirrhotic patients, which may improve the
clinical prognosis of cirrhosis.
Keywords: metabolome, liver cirrhosis, gut microbiota, SCFAs, amino acid
INTRODUCTION
The liver plays a pivotal role in material metabolism, such as synthesis of proteins, detoxification,
and storage. Liver lesions will inevitably lead to a change in related metabolic network. Cirrhosis,
often preceded by hepatitis and steatosis, is a condition in which the liver does not function
properly due to long-term damage. Cirrhosis resulted in 1.2 million deaths in 2013, up from
Abbreviations: ADH, alcohol dehydrogenase; ALD, alcoholic liver disease; ALDH, acetaldehyde dehydrogenase; CTP, Child-
Turcotte-Pugh; EPA, eicosapntemacnioc acid; HCC, hepatocellular cancer; HCT, hierarchical condition tree; HPLC-GC/MS-
MS, high-performance liquid phase chromatography and gas chromatography coupled with tandem mass spectrometry; LPS,
lipopolysaccharide; MFE, molecular feature extraction; NAFLD, non-alcoholic fatty liver disease; PCA, principle component
analysis; PLS-DA, partial least squares discriminant analysis; QC, quality control; SCFAs, short-chain fatty acids.
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0.8 million deaths in 1990 (GBD 2013 Mortality and Causes of
Death Collaborators, 2015). Independent of the cause, treatment
of cirrhosis partly depends on the underlying cause, with the
principle of preventing worsening and complications.
The liver anatomy exhibits its close interaction with the gut
(Szabo, 2015). Liver dysfunction causes serious complications,
such as bacteremia, ascites, and hepatic encephalopathy,
accompanied by increased intestinal permeability and changed
intestinal microenvironment, resulting in intestinal microbiota
dysbiosis and dysfunction (Garcovich et al., 2012; Quigley
et al., 2013; Minemura and Shimizu, 2015). Human intestinal
microbiota was an important organ which has been neglected
for a long time. The human gut harbors up to 100 trillion
microbes and encode 100-fold more unique genes than the
human genome, which were regarded as the “second genome”
of the body (Martínez et al., 2013). Microbial communities
were dominated by members of just two bacterial phyla,
Bacteroidetes and Firmicutes (Eckburg et al., 2005). Obligate
anaerobes, such as Bacteroides, Bifidobacterium, Bacillus,
and Peptostreptococcus, account for 99.9% of the intestinal
microbiota, with Bacteroides and Bifidobacterium accounting
for 55% of them. Most of the resident microbes in the gut
have a profound influence on human physiology and nutrition.
The gut flora function as a bioreactor for autonomous and
co-metabolism and can regulate responses within the host to
external stimuli, and perform useful functions (Del Chierico
et al., 2014), such as fermenting undigestible compounds
to produce energy, training the immune system, providing
nutrition for intestinal epithelial cells, preventing growth of
pathogens, providing vitamins (such as biotin and vitamin
K) for host. There were accumulating evidence available
implicating that extensive modification and imbalances of the
gut microbiota and its microbiome were responsible for many
human disease, such as bacterial endocarditis, heart disease,
cancer, pneumonia, atherosclerosis, preterm low birth weight,
chronic kidney disease, obesity, and pancreatic cancer (Steinhoff,
2005).
In the past few years, more and more research were
focused on the intestinal microbiota community in patients
with hepatopathy. Ahluwalia et al. (2016) enrolled 40 controls
and 147 cirrhotic patients (87 with hepatic encephalopathy),
and researched on the relationship between stool microbiota
and brain magnetic resonance imaging (MRI), with the results
shown negative linkages between autochthonous families and
positive ones between Enterobacteriaceae to MR spectroscopy
and hyperammonemia-associated astrocytic changes. Gra˛t et al.
(2016) analyzed the gut microbial profile from 15 patients
with hepatocellular cancer (HCC) and 15 non-HCC patients,
which suggested that the overgrowth of E coli in the gut
may contribute to the process of hepatocarcinogenesis. Usami
et al. (2013) collected fecal samples from 46 hepatic cancer
patients, followed by the evaluation of fecal constituents
and lipid and fatty acid concentrations, and suggested that
intestinal microbiota affected serum fatty acid metabolism and
were modified by liver disorders. Bajaj et al. (2015) collected
fecal and salivary samples from 102 cirrhotic patients (43
previous hepatic encephalopathy) and 32 controls, followed by
stool/saliva microbiome composition and function analysis, as
well as systemic inflammatory evaluation, to evaluate the oral
microbiome in cirrhosis and compare with stool microbiome.
Fecal samples were collected from 15 compensated cirrhotic
patients and 15 age-matched controls to evaluate changes in
stool microbiota composition and function in cirrhotic patients
after omeprazole therapy, and they found that omeprazole
was associated with a microbiota shift and functional change
in the distal gut in compensated cirrhotic patients that
could set the stage for bacterial overgrowth (Bajaj et al.,
2014). Chen et al. (2014) researched on fecal samples from
12 alcoholic cirrhosis patients, 18 hepatitis B virus related
cirrhosis patients, and 12 normal controls using a specific
functional gene array, which suggested that the functional
composition of fecal microbiota was heavily influenced by
cirrhosis, especially by alcoholic cirrhosis. Gra˛t et al. (2014)
confirmed the enrichment of lactobacilli in the gut microflora
of liver transplant candidates with cirrhosis as revealed by
intestinal flora component analysis. Seventeen cirrhotic patients
and 24 healthy individuals were recruited and subjected to
fecal metabolites detection, which suggested the accompany
of malabsorption with disorders of fatty acid metabolism,
potentially due to changes in gut microflora (Huang et al., 2013).
Park et al. (2016) suggested that alcoholic liver disease should
be considered in the aspect of both gut health and chronic
systemic low-grade inflammation. Given the above, hepatopathy
had a significant impact on the component and function of gut
microbiota via gut–liver axis. However, few intensive studies
have investigated the Child-Turcotte-Pugh (CTP) score related
metabolic interactions between the gut and liver, as well as the
correlation between gut flora component and metabolism. Our
study highlighted the association and communication between
gut flora community and metabolism and researched how the
intestinal microbiota regulated systemic metabolic changes in
cirrhotic patients.
MATERIALS AND METHODS
Study Participants and Fecal Samples
The severity and prognosis of cirrhosis was classified with
the CTP scoring system, which was based on bilirubin,
albumin, prothrombin time, presence and severity of ascites,
and encephalopathy. In this study, a total of 13 individuals,
including 10 cirrhotic patients (five of CTP score A, five of
CTP score B) and three healthy individuals were enrolled with
informed consent. Class A patients had a favorable prognosis,
while symptome of class B patients was more severe clinically. All
the participants were 40–60 years old, with a normal body mass
index and had no dietary preferences. Cirrhosis was diagnosed by
liver biopsy in all patients. None of these patients had comorbid
diseases. All healthy individuals had normal liver biochemistry
tests without evidence of hepatic or other diseases. Exclusion
criteria included a history of antibiotics, probiotics, steroids,
or other hormones ingestion (including oral, intramuscular or
intravenous) within the previous 3 months of stool sampling.
This study was approved by the Institutional Review Board of
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Affiliated Hospital of Academy of Military Medical Sciences. All
participants signed an informed consent form prior to entering
the study. The study conformed to the ethical guidelines of the
1975 Declaration of Helsinki.
16S rRNA Gene Amplicon Library
Preparation and Sequencing
Microbial DNA extraction was performed using the QIAamp
DNA Stool Mini Kit (Cat No: 51504) with 220 mg of fecal
sample. Metagenomic sequencing of 16S rRNA gene V1–V3
region was performed with the MiSeq platform (Illumina Inc.,
San Diego, CA, USA) using version 3 (300 × 2) chemistry on
the MiSeq instrument (Illumina) according to manufacturer’s
instructions (Kozich et al., 2013). Library preparation and
sequencing were performed as previously described (Mwaikono
et al., 2016).
Metabolite Extraction and Separation
Fresh fecal samples were taken from all participants for
metabolites extraction. Metabolites extraction was performed
by adding 1.2 ml of cold (−80◦C) high performance liquid
chromatography (HPLC)-grade methanol to fecal samples.
Samples were vortex-mixed followed by sonicated for 30 s
(Sonicator R© 3000; Misonix) on liquid nitrogen. This protocol
was repeated five times with a 60-min storage period at
−80◦C between each cycle. The final pellet was removed by
centrifugation at 16,000 rpm for 10 min at 4◦C, and the
supernatant was stored at −80◦C. The methanolic extract
was centrifuged at 13,000 rpm for 20 min at 4◦C to
precipitate any solid impurity. The supernatant was analyzed
by high-performance liquid phase chromatography and gas
chromatography coupled with tandem mass spectrometry
(HPLC-GC/MS-MS, Metabolon, Inc., Durham, NC, USA) as
described previously (Sha et al., 2010).
Metabolites Identification and Data Processing
Samples were analyzed in one randomized run, during which
time they were kept in the liquid phase chromatography
autosampler at 4◦C. Background noise and unrelated
ions were removed from the resulting data file using the
Molecular Feature Extraction (MFE) tool in the Mass Hunter
Qualitative Analysis software (B.06.00, Agilent). Filtering
and alignment of primary data were performed with Mass
Profiler Professional software (version 13.0, Agilent). The
multivariate analyses were performed using SIMCA-P+
software (12.0.1.0, Umetrics) to generate a partial least squares
discriminant analysis (PLS-DA) model with all the variables,
and quality controls (QCs) were predicted into this model.
These data were then represented in a hierarchical condition
tree (HCT). Their identities were confirmed by comparing
the fragments that were obtained with the structure of the
proposed compound in the MS/MS spectra in a public database
(METLIN: https://metlin.scripps.edu/metabolites_list.php)
or against commercially available standards. Wilcoxon rank-
sum test method was used to assess the metabolites with
significant differences in abundance between patients and the
normal.
RESULTS
Methodology and Study Population
A compositional survey of metabolites from fecal samples was
used to identify cirrhosis related characteristics in microbes’
metabolic activity. In this study, we recruited and investigated
cirrhotic patients with CTP score of A (AP, n = 5) and CTP
score of B (BP, n = 5), and normal individuals (NM, n = 3). The
information and characteristics of all the recruited subjects were
reported in Table 1. A full description of the methods is available
in the Section “Materials and Methods.”
Cirrhosis Related Composition of the
Intestinal Microbiota
The microbial composition of fecal samples was analyzed by
pyrosequencing of 16S rRNA gene. The bacterial community
Chao 1 diversity and phylogenetic diversity measures were
determined, which revealed a significant decrease in microbial
diversity from cirrhotic patients, even more remarkable in BP
patients (Figure 1A). Fecal microbiota community, in especial
Firmicutes, Proteobacteria, and Bacteroidetes, from cirrhotic
patients was clearly different from the normal (Figure 1B).
Samples from BP patients contained a significant reduction
of Bacteroidetes and increase in Firmicutes and Proteobacteria
compared with the normal. Overall, fecal microbiota component
from AP patients had no significant difference compared with
the normal, which may largely due to that gut microbiota were
in compensatory state at the early stage of disease. In the family
level, fecal microbiota from the cirrhotic patients contained
a remarkable absence of Bacteroidaceae, and enhancement of
Enterobacteriaceae, Veillonellaceae, and Streptococcaceae.
Cirrhosis Related Changes in the
Predicted Metabolites
We profiled the fecal microbiota metabolome of the subjects
to explore global metabolic alterations associated with liver
cirrhosis. A total of 108 metabolites were robustly identified,
and 51 metabolites had different abundance between cirrhotic
patients and the normal (Supplementary Table S1). The fecal
samples of cirrhotic patients were clearly differentiated from
the normal as shown by the principal coordinates analysis
based on unweighted unifrac distances (Figure 2A). To further
elucidate the CTP-dependent impact on the fecal microbiota
metabolism, we separately performed hierarchical clustering on
the relative metabolite concentration for the detected metabolites
which have suggested that fecal samples from the normal
could be clearly distinguished from the samples taken from
the patients (Figure 2B). The fecal samples from patients
were characterized by a higher abundance of amino acids
metabolism. A significant increase in the amount of glycine
was detected in patients, whereas other amino acids, such as
glutamic acid, L-glutamic acid, isoleucine, lysine, N-methyl-L-
prolinol, oxoproline, phenylalanine, and valine, were detected
in significantly decreased amounts. In addition, enhanced
carbohydrate metabolism, especially the catabolism of some
sugar alcohol, such as hexadecanol, maltose, mannitol, sorbitol,
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was observed in cirrhotic patients, and correspondingly, its
metabolites, such as organic acid, were detected with a higher
abundance.
In addition, we explored the alterations associated with
cirrhosis (Figure 2C). The relative concentrations of some
unsaturated fatty acids (fumaric acid, hydrocinnamic acid,
and linoleic acid) were generally seen to increase in the
fecal metabolites from cirrhotic patients, especially in class
B patients. Cirrhosis-specific trends were more evident for
amine (cadaverine, tyramine, putrescine), with the cirrhotic
samples showing a large number of increase compared to
the normal. An increase in concentration of some short-
chain fatty acids (SCFAs) and their compounds (butanoic acid,
4-aminobutyric acid, 4-hydroxybutyrate, 5-aminovaleric acid,
carboxylate, lactic acid, pentanoic acid, succinic acid), as well
as bile acids were evident in the metabolites from patients.
In contrast, the median values for some amino acids, such as
glutamic acid, L-glutamic acid, isoleucine, lysine, N-methyl-L-
prolinol, oxoproline, phenylalanine, valine, were generally found
to decrease in the fecal samples from cirrhotic patients. In
addition, we detected some sugar alcohol (hexadecanol, maltose,
mannitol, sorbitol) were significantly decreased in cirrhotic
patients.
Cirrhosis Related the
Microbiota–Metabolite Correlations
Correlation analysis was conducted to further explore the
association between fecal microbiota and metabolites. Overall,
the microbiota–metabolite correlations changed in cirrhotic
patients (Figure 3), indicating that the initial equilibrium of
co-occurring microbial species was perturbed by cirrhosis. We
found that Fusobacteria, enhanced in the fecal microbiota
community in cirrhotic patients, was positively correlated
with cadaverine (R = 0.85) and cholic acid (R = 0.6).
Tenericutes, contained a decreased abundance in cirrhotic
patients, was positively correlated with hexanoic acid (R > 0.99),
heptanoic acid (R > 0.99), N-methyl-L-prolinol (R = 0.62),
and hexadecanol (R = 0.62). Synergistetes, had a decreased
abundance in cirrhotic patients, was positively correlated with
butylpentamethyldisiloxane (R = 0.77), valine (R = 0.67), D-
galacturonic acid (R = 0.63), sorbitol (R = 0.61). Acidobacteria,
Fibrobacteres, Elusimicrobia, and Spirochaetae were all positively
correlated with 4-hydroxybutyrate (R= 0.93) and hydrocinnamic
acid (R = 0.93). In addition, butanoic acid and pentanoic acid
were negatively correlated with almost all the bacteria, except
Bacteroidetes (R = 0.4). Succinic acid was positively correlated
with Actinobacteria (R = 0.8). Glutaric acid was positively
correlated with Synergistetes (R = 0.67) and Tenericutes
(R = 0.64). Linoleic acid was positively correlated with
Lentisphaerae (R = 0.6), which is a phylum of bacteria closely
related to Verrucomicrobia. Isoleucine was positively correlated
with Synergistetes (R = 0.67) and Fusobacteria (R = 0.62).
Hydrocinnamic acid was positively correlated with Synergistetes
(R = 0.67) and Verrucomicrobia (R = 0.61). Oxoproline
was positively correlated with Proteobacteria (R = 0.79) and
Synergistetes (R = 0.67). Heptadecanoic acid was positively
correlated with Verrucomicrobia (R = 0.6). Deoxycholic
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FIGURE 1 | Characteristics of fecal microbiota community from the study population. (A) Averaged number of richness (Chao 1) and diversity (PD, whole
tree) of fecal samples from the subjects. The centered line represents the median value of NM (red), AP (blue), and BP (green), the top and bottom represent the 95th
and 5th percentile of the data, respectively. (B) Relative abundance (%) of predicted bacterial phylum in the fecal microbiota community from cirrhotic patients and
the normal.
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FIGURE 2 | Characteristics of metabolites from fecal samples of cirrhotic patients compared with the normal. (A) Principle component analysis (PCA).
The analysis was based on unweighted UniFrac distance matrix of all metabolites concentrations from fecal samples of the cirrhotic patients (AP and BP) and the
normal. (B) Color-coded heat map displaying the cirrhosis related relative fecal metabolites amounts compared to the normal. Hierarchical clustering of the metabolic
profiling data at NM (red bars), AP (blue bars), BP (green bars). The color scale represents the scaled abundance of each metabolite, denoted as Z-score, with red
and blue indicated increased and decreased concentrations, respectively. (C) Cirrhosis related common sets of metabolic perturbations. Fecal samples of the
subjects were taken for metabolic profiling. The values displayed are the average concentrations of each metabolite. Columns are colored according to the groups:
red: NM; blue: AP; green: BP. Data are shown as mean values ± SD for each group.
acid was positively correlated with Tenericutes (R = 0.82),
Verrucomicrobia (R= 0.62).
DISCUSSION
The host and its gut microbiota coproduce a wide spectrum
of small molecules during the cometabolism of compounds
in diet and xenobiotics, and the intestinal cometabolism
play critical roles in communication and interaction between
host organs and the host’s gut flora symbionts. Our data
indicated pronounced shifts in gut bacterial community and
metabolome associated with cirrhosis. The metabolic materials
from cirrhotic fecal samples had a higher abundance of
amine, unsaturated fatty acid, and SCFAs, whereas a lower
abundance of sugar alcohol and amino acid, similar with
previous research from Wei et al. (2013), which suggested
that fecal microbiota from cirrhotic patients contained an
enrichment in amino acid transport and metabolism, energy
production and conversion, secondary metabolites biosynthesis,
transport and catabolism as revealed by metagenomic
approach.
Some amino acids were significantly decreased in fecal
metabolites from cirrhotic patients. Glutamic acid is non-
essential for human, meaning the body can synthesize it, and
95% of the dietary glutamate is metabolized by intestinal cells
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FIGURE 3 | The correlation analysis between the abundance of fecal metabolites (A) and fecal microbiota composition, with the data shown as logarithm
value, (B) among the subjects.
in a first pass. Isoleucine, lysine, phenylalanine, and valine are
essential amino acids for human because they cannot be created
from other compounds by the human body and so must be
taken in as food. Amine was the main products of decomposition
of amino acid. Cadaverine, similar with putrescine, is the
decarboxylation product of the amino acid lysine and is a foul-
smelling toxic diamine compound produced by the putrefaction
of animal tissue. Tyramine is a naturally occurring monoamine
compound and trace amine derived from the amino acid
tyrosine. Production of cadaverine, tyramine, putrescine in
human gut was strongly associated with intestinal microbiota
which can decompose amino acids, including Fusobacteria,
Proteus, Bacillus, Pseudomonas, and so on, and those bacteria
can form protease and peptidase only when a large number of
breeding. It has been recognized that Fusobacteria is involved in
various human infections causing tissue necrosis and septicemia
(Parte, 2014). In our study, cadaverine, showing a large number
of increase compared to the normal in the cirrhotic samples, was
positively correlated with Fusobacteria, and the amino acids were
significantly decreased in cirrhotic fecal metabolites, indicating
an enhanced amino acids-degrading activity of Fusobacteria in
human gut from cirrhotic patients.
Hexadecanol, positively correlated with Tenericutes, is a
fatty alcohol with the formula CH3(CH2)15OH. Maltose is a
disaccharide formed from two units of glucose. In human
gut, maltose is broken down by the enzyme maltase so that
there are two glucose molecules from which the glucose
metabolism obtains energy. Mannitol, as one of the most
abundant energy and carbon storage molecules in nature,
was produced by plethora of organisms, including bacteria,
fungi, algae, and many plants (Song and Vieille, 2009).
Sorbitol is a sugar alcohol with a sweet taste, which could be
metabolized slowly by human body. Sorbitol and valine were
both positively correlated with Synergistetes, which suggested to
be opportunistic pathogens and inhabit a majority of anaerobic
environments, including gastrointestinal tracts, have also been
implicated in gastrointestinal infections and soft tissue infections
(Marchandin et al., 2010).
SCFAs are end-product of anaerobic fermentation, called
saccharolytic fermentation, performed by beneficial colonic
bacteria that feed on, or ferment prebiotics, which are plant
products that contain adequate amounts of dietary fiber
(Van Immerseel et al., 2005). SCFAs are significant sources
of energy for gut enterocytes, providing a major source of
useful energy and nutrients for human, helping the body to
absorb essential dietary minerals such as calcium, magnesium,
and iron (Clarke et al., 2014), influencing the gastrointestinal
barrier function to reduce pathogenic bacterial colonization
(Brahe et al., 2013), benefiting the colonocytes by increasing
energy production and cell proliferation, and may protect
against colon cancer (Charalampopoulos et al., 2002). Moreover,
emerging research suggested the role for SCFAs in reducing
and controlling inflammation (Samuel et al., 2008). Miyoshi
et al. (2011) confirmed that oral tributyrin administration
increased plasma butyrate level in the portal vein by one to
two orders of magnitude, and attenuated NF-κB activation and
lipopolysaccharide (LPS)-induced acute liver tissue injury in rats.
Two reports from Bloemen et al. (2009, 2010) confirmed the role
of the gut and liver in SCFAs exchange by measuring portal and
hepatic venous SCFA concentrations in vivo, which were shown
that intestinal SCFAs release by the gut was equally to hepatic
uptake, liver of cirrhosis was able to use butyrate and propionate,
most likely preventing increased systemic concentrations. In
this study, we found that butanoic acid and pentanoic acid
were negatively correlated with almost all the bacteria, except
Bacteroidetes. Opportunistic pathogens were overexpressed
in the fecal microbiota community from cirrhotic patients,
still there were Bacteroidetes which metabolize carbohydrate
into SCFAs to benefit the intestine, playing a compensatory
role for the dysfunction of intestinal microenvironment. 4-
Hydroxybutyrate was positively correlated with Acidobacteria,
Fibrobacteres, Elusimicrobia, and Spirochaetae. Cells produce
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4-hydroxybutyrate by reduction of succinic semialdehyde
via succinic semialdehyde reductase, and 4-hydroxybutyrate
could be degraded into succinic acid under the action of
alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase
(ALDH). Succinic acid was positively correlated with
Actinobacteria, and followed by Firmicutes. Actinobacteria,
which had an increased abundance in the fecal microbiota
from cirrhotic patients, are of great economic importance to
humans and are recognized as the producers of many bioactive
metabolites useful to humans. In addition, Hexanoic acid and
heptanoic acid were both positively correlated with Tenericutes.
Glutaric acid was the metabolite production in both fatty acid
degradation (map00071) and lysine degradation (map00310)
pathway and positively correlated with Synergistetes and
Tenericutes. Increased abundance of SCFAs in fecal metabolites
suggested the enhanced ability of carbohydrate metabolism
in cirrhotic patients. Due to the complex component of gut
microbiota, various SCFAs were detected positively correlated
with different bacterial taxa. Our results showed that fermentative
subsets of gut bacterial taxa might be selectively stimulated
by carbohydrate and might therefore be capable of consuming
plant-derived saccharides in human gut.
Bile acids, composed of individual bile acid moieties, mucous,
phospholipids, and biliverdin (Begley et al., 2005), function
as systemic signaling molecules, and their main physiological
roles in the small intestine are emulsification of fats, release
of fat-soluble vitamins, regulation of cholesterol metabolism
(Swann et al., 2011; Vaquero et al., 2013). Interdependent
relationship existed between intestinal microbiota and bile
acids. On the one hand, intestinal microbiota was vital for
the transformation of bile acids. Conjugated bile salts secreted
into the enteric cavity are hydrolyzed and dehydroxylated
by bile salt hydrolases (BSHs), predominantly secreted by
Bacteroides and Fusobacteria (Hofmann, 1999), and as a
result, cholic acids were converted into deoxycholic acid, and
chenodeoxycholic acid into lithocholic acid. On the other hand,
the dissociation of conjugated bile acids can provide carbon
source, nitrogen source, and energy for intestinal microbiota.
The amount of fecal bile acids was influenced by many factors.
In cirrhotic patients, abated liver function and the dysbiosis
and dysfunction in fecal microbiota resulted in the declined
role of dissociation and dehydroxylation for bile acid. Bile acid
metabolism was disordered, and the reabsorption in the colon
was decreased, so more bile acid was detected in the fecal
metabolites.
Above all, it should be noticed that albeit the gut flora function
is always changing, it is also relatively stable, and has evolved
specialized core functions that are maintained under different
conditions (Moya and Ferrer, 2016). Cirrhotic patients have weak
constitution, and as a result the body tissues need to enhance their
expenditure and degradation of materials to partially compensate
for the increased demand for nutrients and energy, and the fecal
microbiota seemed to play compensatory and regulation roles,
which may provide more nutrients and energy resources for
the patients. As a result, most amino acid and sugar alcohol,
which were few detected from cirrhotic samples, were further
metabolized into a large number of small molecule metabolites,
such as amine, unsaturated fatty acid, and SCFAs.
CONCLUSION
Altogether, our data indicated that the relationship between
some gut flora and humans is not merely non-harmful
coexistence, but rather a symbiotic relationship (Del Chierico
et al., 2014). The liver is the central organ in host metabolism.
At present, treatment of cirrhosis is partly based on the
principle of preventing worsening and complications depending
on the underlying cause. Our study will improve the prognosis
and provide fundamental basis for interventions of cirrhosis
progress and related infectious and non-infectious complications,
including metabolic disorders induced by the gut–liver axis,
especially alcoholic liver disease (ALD), non-alcoholic fatty liver
disease (NAFLD) and hepatocarcinogenesis.
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